Business, energy, technology, markets and global industry news from Business News Today

NEALS

PharmaDeviceNews NEALS
Infographic highlighting Darwin Biotech’s early ALT001 functional and neurofilament light chain (NfL) signals in amyotrophic lateral sclerosis (ALS), alongside plans for a U.S. clinical trial evaluating higher doses and longer treatment.
Pharma & Biotech

Darwin Biotech reports early ALS functional and NfL signals from randomised Phase 1 ALT001 study

Darwin Biotech reports early ALT001 functional and NfL signals in ALS, with a US trial planned to test higher doses and longer treatment.

Read More